One Investor on What Expanded Stem Cell Research May, or May Not, Mean to His Industry
Yesterday, the Obama administration announced its decision to overturn restrictions on federal funding for embryonic stem cell research. To find out what it will mean to startups, along with who is most likely to benefit from the reversal first and why, I spoke just now with venture capitalist Chris Christoffersen, a Boulder, Colo.-based partner in the healthcare practice of Morgenthaler Ventures, who sits on the boards of two stem cell companies.
10 March 2009•3 mins read
